Sandoz and Aurobindo have cancelled their billion-dollar deal through which the Indian company was planning to acquire Sandoz’ generic oral solids and dermatology businesses in the US.
Citing a delay in US Federal Trade Commission approval for the deal following a protracted bid to obtain clearance, Sandoz...





